Clinical PET/MR Imaging in Dementia and Neuro-Oncology.
暂无分享,去创建一个
[1] N. Galldiks,et al. From the clinician's point of view - What is the status quo of positron emission tomography in patients with brain tumors? , 2015, Neuro-oncology.
[2] Karl-Josef Langen,et al. O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas. , 2005, Brain : a journal of neurology.
[3] A. Mishra,et al. Glioma Recurrence Versus Radiation Necrosis: Single-Session Multiparametric Approach Using Simultaneous O-(2-18F-Fluoroethyl)-L-Tyrosine PET/MRI , 2016, Clinical nuclear medicine.
[4] Koen Van Laere,et al. EANM procedure guidelines for PET brain imaging using [18F]FDG, version 2 , 2009, European Journal of Nuclear Medicine and Molecular Imaging.
[5] Stefan Sunaert,et al. Presurgical planning for tumor resectioning , 2006, Journal of magnetic resonance imaging : JMRI.
[6] Osama Sabri,et al. PET/MR in dementia and other neurodegenerative diseases. , 2015, Seminars in nuclear medicine.
[7] Eugen Trinka,et al. [18F]-fluoro-ethyl-L-tyrosine PET: a valuable diagnostic tool in neuro-oncology, but not all that glitters is glioma. , 2013, Neuro-oncology.
[8] H. Herzog,et al. Role of O-(2-18F-Fluoroethyl)-l-Tyrosine PET for Differentiation of Local Recurrent Brain Metastasis from Radiation Necrosis , 2012, The Journal of Nuclear Medicine.
[9] Nick C Fox,et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria , 2014, The Lancet Neurology.
[10] Junia C Costa,et al. Impact of [18F]-fluoro-ethyl-tyrosine PET imaging on target definition for radiation therapy of high-grade glioma. , 2015, Neuro-oncology.
[11] James M. Provenzale,et al. Principles of T2*‐weighted dynamic susceptibility contrast MRI technique in brain tumor imaging , 2015, Journal of magnetic resonance imaging : JMRI.
[12] J. Tonn,et al. MRI-suspected low-grade glioma: is there a need to perform dynamic FET PET? , 2012, European Journal of Nuclear Medicine and Molecular Imaging.
[13] Gereon R Fink,et al. Comparison of 18F-FET PET and Perfusion-Weighted MR Imaging: A PET/MR Imaging Hybrid Study in Patients with Brain Tumors , 2014, The Journal of Nuclear Medicine.
[14] Rasmus Larsen,et al. Motion Tracking for Medical Imaging: A Nonvisible Structured Light Tracking Approach , 2012, IEEE Transactions on Medical Imaging.
[15] Kenneth Rockwood,et al. Diagnostic Criteria for Vascular Cognitive Disorders: A VASCOG Statement , 2014, Alzheimer disease and associated disorders.
[16] Long Jiang Zhang,et al. PET/MRI of central nervous system: current status and future perspective , 2016, European Radiology.
[17] P. Visser,et al. New MRI markers for Alzheimer's disease: a meta-analysis of diffusion tensor imaging and a comparison with medial temporal lobe measurements. , 2012, Journal of Alzheimer's disease : JAD.
[18] S. Goldman,et al. Results of positron emission tomography guidance and reassessment of the utility of and indications for stereotactic biopsy in children with infiltrative brainstem tumors. , 2007, Journal of neurosurgery.
[19] A. Drzezga,et al. Current status and future role of brain PET/MRI in clinical and research settings , 2015, European Journal of Nuclear Medicine and Molecular Imaging.
[20] F. Berthold,et al. [11C]-l-Methionine positron emission tomography in the management of children and young adults with brain tumors , 2009, Journal of Neuro-Oncology.
[21] Mike P. Wattjes,et al. Cerebral perfusion and glucose metabolism in Alzheimer’s disease and frontotemporal dementia: two sides of the same coin? , 2015, European Radiology.
[22] J. Barnholtz-Sloan,et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. , 2012, Neuro-oncology.
[23] Martina Bocchetta,et al. Imaging markers for Alzheimer disease , 2013, Neurology.
[24] Janet S. Reddin,et al. Direct comparison of fluorodeoxyglucose positron emission tomography and arterial spin labeling magnetic resonance imaging in Alzheimer's disease , 2012, Alzheimer's & Dementia.
[25] Kingshuk Roy Choudhury,et al. Predicting cognitive decline in subjects at risk for Alzheimer disease by using combined cerebrospinal fluid, MR imaging, and PET biomarkers. , 2013, Radiology.
[26] A. Luna,et al. Clinical Imaging of Tumor Metabolism with ¹H Magnetic Resonance Spectroscopy. , 2016, Magnetic resonance imaging clinics of North America.
[27] I. Pollack,et al. Childhood brain tumors: epidemiology, current management and future directions , 2011, Nature Reviews Neurology.
[28] N. Bohnen,et al. Effectiveness and Safety of 18F-FDG PET in the Evaluation of Dementia: A Review of the Recent Literature , 2012, The Journal of Nuclear Medicine.
[29] N. Albert,et al. Early static 18F-FET-PET scans have a higher accuracy for glioma grading than the standard 20–40 min scans , 2015, European Journal of Nuclear Medicine and Molecular Imaging.
[30] R. Koeppe,et al. A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[31] D. Kondziolka,et al. Concurrent functional and metabolic assessment of brain tumors using hybrid PET/MR imaging , 2016, Journal of Neuro-Oncology.
[32] Jörg-Christian Tonn,et al. Value of O-(2-[18F]fluoroethyl)-l-tyrosine PET for the diagnosis of recurrent glioma , 2004, European Journal of Nuclear Medicine and Molecular Imaging.
[33] B. Bender,et al. Metabolic Mapping of Gliomas Using Hybrid MR-PET Imaging: Feasibility of the Method and Spatial Distribution of Metabolic Changes , 2013, Investigative radiology.
[34] G. Zaharchuk,et al. Recommended implementation of arterial spin-labeled perfusion MRI for clinical applications: A consensus of the ISMRM perfusion study group and the European consortium for ASL in dementia. , 2015, Magnetic resonance in medicine.
[35] E. Hoving,et al. The role of diffusion tensor imaging in brain tumor surgery: A review of the literature , 2014, Clinical Neurology and Neurosurgery.
[36] R. Mirimanoff,et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.
[37] S. Holm,et al. Region specific optimization of continuous linear attenuation coefficients based on UTE (RESOLUTE): application to PET/MR brain imaging , 2015, Physics in medicine and biology.
[38] Ian Law,et al. Combined PET/MR imaging in neurology: MR-based attenuation correction implies a strong spatial bias when ignoring bone , 2014, NeuroImage.
[39] G. Frisoni,et al. Visual versus semi-quantitative analysis of 18F-FDG-PET in amnestic MCI: an European Alzheimer's Disease Consortium (EADC) project. , 2015, Journal of Alzheimer's disease : JAD.
[40] W. Koch,et al. Analysis of 18F-FET PET for grading of recurrent gliomas: is evaluation of uptake kinetics superior to standard methods? , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[41] Gereon R Fink,et al. The Usefulness of Dynamic O-(2-18F-Fluoroethyl)-l-Tyrosine PET in the Clinical Evaluation of Brain Tumors in Children and Adolescents , 2015, The Journal of Nuclear Medicine.
[42] Ciprian Catana,et al. PET/MRI for Neurologic Applications , 2012, The Journal of Nuclear Medicine.
[43] C. Jack,et al. Age-specific population frequencies of cerebral β-amyloidosis and neurodegeneration among people with normal cognitive function aged 50–89 years: a cross-sectional study , 2014, The Lancet Neurology.
[44] Hans-Jakob Steiger,et al. Multimodal metabolic imaging of cerebral gliomas: positron emission tomography with [18F]fluoroethyl-L-tyrosine and magnetic resonance spectroscopy. , 2005, Journal of neurosurgery.
[45] P. Wen,et al. Glioma in 2014: Unravelling tumour heterogeneity—implications for therapy , 2015, Nature Reviews Clinical Oncology.
[46] Anna Barnes,et al. A comparison of CT- and MR-based attenuation correction in neurological PET , 2014, European Journal of Nuclear Medicine and Molecular Imaging.
[47] J. Morris,et al. The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.
[48] H. Larsson,et al. Simultaneous evaluation of brain tumour metabolism, structure and blood volume using [18F]-fluoroethyltyrosine (FET) PET/MRI: feasibility, agreement and initial experience , 2015, European Journal of Nuclear Medicine and Molecular Imaging.
[49] Jochen Herms,et al. FET PET for the evaluation of untreated gliomas: correlation of FET uptake and uptake kinetics with tumour grading , 2007, European Journal of Nuclear Medicine and Molecular Imaging.
[50] Toshinori Hirai,et al. Usefulness of diffusion‐weighted MRI with echo‐planar technique in the evaluation of cellularity in gliomas , 1999, Journal of magnetic resonance imaging : JMRI.
[51] Ching-Hon Pui,et al. Challenging issues in pediatric oncology , 2011, Nature Reviews Clinical Oncology.
[52] C. Johansen,et al. Educational attainment among survivors of childhood cancer: a population-based cohort study in Denmark , 2004, British Journal of Cancer.
[53] M Kirkpatrick,et al. Cerebral Blood Volume Measurements by Perfusion-Weighted MR Imaging in Gliomas: Ready for Prime Time in Predicting Short-Term Outcome and Recurrent Disease? , 2009, American Journal of Neuroradiology.